Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 Jul;39(7):2729-31.
doi: 10.1128/JCM.39.7.2729-2731.2001.

Comparative evaluation of penicillin, ampicillin, and imipenem MICs and susceptibility breakpoints for vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium

M P Weinstein  1
Affiliations
Comparative Study

Comparative evaluation of penicillin, ampicillin, and imipenem MICs and susceptibility breakpoints for vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium

M P Weinstein. J Clin Microbiol. 2001 Jul.

Abstract

Although imipenem has in vitro activity against Enterococcus faecalis and Food and Drug Administration-approved indications for treatment of infections caused by this microorganism, there are no NCCLS guidelines for susceptibility testing of imipenem versus enterococci. Therefore, the in vitro activities of penicillin, ampicillin, imipenem, and vancomycin against 201 blood isolates of E. faecalis and 24 blood isolates of Enterococcus faecium were compared. The susceptibility of isolates to penicillin or ampicillin accurately predicted the in vitro activity of imipenem. Since the susceptibility of enterococci to imipenem can be predicted by the results obtained by testing of penicillin or ampicillin, testing of imipenem by clinical laboratories probably is not necessary.

PubMed Disclaimer

Comment in

References

    1. Cohn D L, Reimer L G, Reller L B. Comparative in-vitro activity of MK0787 (N-formimidoyl thienamycin) against 540 blood culture isolates. J Antimicrob Chemother. 1982;9:183–194. - PubMed
    1. Eliopoulos G M, Moellering R C., Jr Susceptibility of enterococci and Listeria monocytogenes to N-formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother. 1981;19:789–793. - PMC - PubMed
    1. Facklam R R, Sahm D F, Teixeira L M. Enterococcus. In: Murray P R, Baron E J, Pfaller M A, Tenover F C, Yolken R H, editors. Manual of clinical microbiology. 7th ed. Washington, D.C.: American Society for Microbiology; 1999. pp. 297–305.
    1. Horadam V W, Smilack J D, Montgomery C L, Werringloer J. In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin. Antimicrob Agents Chemother. 1980;18:557–561. - PMC - PubMed
    1. Kropp H, Gerckens L, Sundelof J G, Kahan F M. Antibacterial activity of imipenem: the first thienamycin antibiotic. Rev Infect Dis. 1985;7(Suppl.):S411–S416. - PubMed

Publication types

MeSH terms